The Melanoma Question With Melanotan

One of the most important discussions about Melanotan 2 in this community is the melanoma question — and members handle it carefully.

The core issue: MT-2 stimulates melanin production and can darken existing moles, which directly interferes with the clinical surveillance that dermatologists rely on to detect melanoma early (the ABCDE criteria include color change and darkening). If a mole changes because of MT-2, it becomes much harder to tell whether that change is benign (peptide-driven) or malignant (early melanoma).

This is not a theoretical concern. Members with personal or family history of melanoma, or with many moles, are especially cautious. The thread below emphasizes that anyone using melanocortin agents needs regular dermatologic surveillance and should never let peptide-driven pigmentation changes go unevaluated. This is one of the clearest examples of why this community frames everything as research context, not casual self-use.